Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CFTR | P13569 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195591 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL2900514 | 0.80 | KDM4E (0.59) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL23015343 | 0.80 | KDM4E (0.51) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL12021817 | 0.79 | KDM4E (0.51) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL24324843 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL29611549 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL16411016 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL2391637 | 0.78 | CFTR (0.63) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL24413980 | 0.77 | KDM4E (0.47) | KDM4EALDH1A1CFTRGAAHSD17B10 | |
| SCHEMBL3616519 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1CFTRGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017593-B1 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | SCRIPPS RESEARCH INST (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-115003383-B | Bicyclic agonists of the interferon Gene stimulator STING | 斯克里普斯研究学院 | 2024-10-01 | — | — | CN | disclosed |
| US-20220332720-A1 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| CN-115003383-A | Bicyclic agonists of interferon gene stimulator STING | 斯克里普斯研究学院 | 2022-09-02 | — | — | CN | disclosed |
| EP-4017593-A1 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | The Scripps Research Institute (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035258-A1 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021035258-A1 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332720-A1 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | STING1, IRF3, IFNAR1 | KDM4E 1800/4885ALDH1A1 3495/4885CFTR 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.